Literature DB >> 25405502

Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes.

Gemma Llauradó1, Ksenia Sevastianova, Sanja Sädevirta, Antti Hakkarainen, Nina Lundbom, Marju Orho-Melander, Per-Henrik Groop, Carol Forsblom, Hannele Yki-Järvinen.   

Abstract

OBJECTIVES: Patients with type 1 diabetes mellitus (T1DM) lack the portal/peripheral insulin gradient, which might diminish insulin stimulation of hepatic lipogenesis and protect against development of nonalcoholic fatty liver disease (NAFLD). We compared liver fat content and insulin sensitivity of hepatic glucose production and lipolysis between overweight T1DM patients and nondiabetic subjects.
MATERIALS AND METHODS: We compared 32 overweight adult T1DM patients and 32 nondiabetic subjects matched for age, body mass index (BMI), and gender. Liver fat content was measured using proton magnetic resonance spectroscopy ((1)H-MRS), body composition by magnetic resonance imaging, and insulin sensitivity using the euglycemic-hyperinsulinemic clamp technique (insulin 0.4 mU/kg · min combined with infusion of D-[3-(3)H]glucose). We also hypothesized that low liver fat might protect from obesity-associated increases in insulin requirements and, therefore, determined insulin requirements across BMI categories in 3164 T1DM patients.
RESULTS: Liver fat content was significantly lower in T1DM patients than in nondiabetic subjects (0.6% [25th-75th quartiles, 0.3%-1.1%] vs 9.0% [3.0%-18.0%]; P < .001). The endogenous rate of glucose production (R(a)) during euglycemic hyperinsulinemia was significantly lower (0.4 [-0.7 to 0.8] mg/kg fat-free mass · min vs 0.9 [0.2-1.6] fat-free mass · min; P = .012) and the percent suppression of endogenous Ra by insulin was significantly greater (89% [78%-112%] vs 77% [50%-94%]; p = .009) in T1DM patients than in nondiabetic subjects. Serum nonesterified fatty acid concentrations during euglycemic hyperinsulinemia were significantly lower (78.5 [33.0-155.0] vs 306 [200.0-438.0] μmol/L; P < .001) and the percent suppression of nonesterified fatty acids significantly higher (89.1% [78.6%-93.3%] vs 51.4% [36.5%-71.1%]; P < .001) in T1DM patients than in nondiabetic subjects. Insulin doses were similar across BMI categories.
CONCLUSIONS: T1DM patients might be protected from steatosis and hepatic insulin resistance. Obesity may not increase insulin requirements in T1DM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25405502     DOI: 10.1210/jc.2014-3050

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

2.  Modeling changes in glucose and glycerol rates of appearance when true basal rates of appearance cannot be readily determined.

Authors:  Laura Pyle; Bryan C Bergman; Kristen J Nadeau; Melanie Cree-Green
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-12-29       Impact factor: 4.310

Review 3.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

Review 4.  Non-alcoholic fatty liver disease and diabetes.

Authors:  Jonathan M Hazlehurst; Conor Woods; Thomas Marjot; Jeremy F Cobbold; Jeremy W Tomlinson
Journal:  Metabolism       Date:  2016-01-11       Impact factor: 8.694

5.  Type 1 Diabetes and Non-Alcoholic Fatty Liver Disease: When Should We Be Concerned? A Nationwide Study in Brazil.

Authors:  Bianca Senger Vasconcelos Barros; Deborah Conte Santos; Marcela Haas Pizarro; Laura Gomes Nunes del Melo; Marilia Brito Gomes
Journal:  Nutrients       Date:  2017-08-15       Impact factor: 5.717

6.  Longitudinal analysis of hepatic transcriptome and serum metabolome demonstrates altered lipid metabolism following the onset of hyperglycemia in spontaneously diabetic biobreeding rats.

Authors:  Simon E Regnell; Martin J Hessner; Shuang Jia; Lina Åkesson; Hans Stenlund; Thomas Moritz; Daria La Torre; Åke Lernmark
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

7.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

Authors: 
Journal:  Obes Facts       Date:  2016-04-08       Impact factor: 3.942

8.  Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes.

Authors:  Ruchi Jain; Türküler Özgümüş; Troels Mygind Jensen; Elsa du Plessis; Magdalena Keindl; Cathrine Laustrup Møller; Henrik Falhammar; Thomas Nyström; Sergiu-Bogdan Catrina; Gun Jörneskog; Leon Eyrich Jessen; Carol Forsblom; Jani K Haukka; Per-Henrik Groop; Peter Rossing; Leif Groop; Mats Eliasson; Björn Eliasson; Kerstin Brismar; Mahmoud Al-Majdoub; Peter M Nilsson; Marja-Riitta Taskinen; Ele Ferrannini; Peter Spégel; Tore Julsrud Berg; Valeriya Lyssenko
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

9.  Reduced hepatocellular lipid accumulation and energy metabolism in patients with long standing type 1 diabetes mellitus.

Authors:  Peter Wolf; Paul Fellinger; Lorenz Pfleger; Sabina Smajis; Hannes Beiglböck; Martin Gajdošík; Christian-Heinz Anderwald; Siegfried Trattnig; Anton Luger; Yvonne Winhofer; Martin Krššák; Michael Krebs
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

10.  Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD.

Authors:  Elina M Petäjä; You Zhou; Marika Havana; Antti Hakkarainen; Nina Lundbom; Jarkko Ihalainen; Hannele Yki-Järvinen
Journal:  Sci Rep       Date:  2016-04-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.